Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Major contract win

16 May 2014 12:25

RNS Number : 3595H
Venn Life Sciences Holdings PLC
16 May 2014
 



Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Major contract win

 

Venn Life Sciences Signs Master Service Agreement for Multi-Country Study

Value is in excess of €3m covering 8 countries in Europe & North America over 18 months

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the securing of a multi-country multi-million euro clinical trials management agreement with a major European biotechnology company.

 

This multi-site agreement will run for over a year and a half, covering seven European countries as well as a number of US sites and is valued in excess of €3m. The clinical trial management programme is for an orphan drug in a rare acute disease area and is proceeding this month.

 

Over the past year Venn has increased its geographic footprint in Europe with new offices in the UK and Germany. Business development has been focused on key growth areas of drug and device development and on winning similar studies across Europe, with a solid pipeline of work for 2014 and 2015 now secured. Studies in rare diseases have increased significantly in recent years and Venn has invested in ensuring they have the critical multi-site agile service capabilities essential to conduct and manage trials efficiently in this sector.

 

Commenting, Venn CEO, Tony Richardson, said:

"We are hearing from many of our clients - in the key pharmaceutical, biotechnology and medical device sectors - of a growing need for a much more agile multi-country clinical trial management capability, especially in the still complex greater European region. Venn has invested heavily in 2013 in preparing the business for a step change in the size and complexity of contracts undertaken. This contract win, and our current pipeline, represent a significant endorsement of our investment strategy since IPO. We have now moved our business focus from small single country projects to larger multicentred projects and we expect to cement this progress with additional project wins in the coming months."

 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla McGuinness, Marketing Manager

Tel: +33 (0)1 30 82 67 07

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - innoVenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBBGDUSDBBGSL
Date   Source Headline
17th Feb 202212:05 pmRNSPositive results from RSV Human Challenge Study
14th Feb 20227:00 amRNSLaunch of STRiVE project
2nd Feb 20227:00 amRNSWorld’s first COVID-19 Characterisation Study
26th Jan 20224:40 pmRNSSecond Price Monitoring Extn
26th Jan 20224:36 pmRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSMalaria Human Challenge Model Launched
21st Dec 20217:00 amRNS£5m Influenza human challenge study contract win
16th Dec 20214:41 pmRNSSecond Price Monitoring Extn
16th Dec 20214:35 pmRNSPrice Monitoring Extension
10th Dec 202111:05 amRNSSecond Price Monitoring Extn
10th Dec 202111:00 amRNSPrice Monitoring Extension
10th Dec 20217:05 amRNSExercise of Options
10th Dec 20217:00 amRNS$13.4m Influenza HCS contract win
6th Dec 20217:00 amRNSPositive results from Flu Human Challenge Study
19th Nov 20217:00 amRNSImutex Vaccine Phase I Study Results
17th Nov 20217:00 amRNS£5.1m RSV contract
15th Nov 20217:00 amRNS£1.5m Contract renewal for Venn Life Sciences
13th Oct 20217:00 amRNSDirectorate Change
20th Sep 20217:00 amRNSHalf-year Report
20th Sep 20217:00 amRNS£5.7m Influenza human challenge study contract win
9th Sep 20217:00 amRNSNotice of Results
7th Sep 20217:00 amRNSPositive results from RSV Human Challenge Study
24th Aug 20219:05 amRNSSecond Price Monitoring Extn
24th Aug 20219:00 amRNSPrice Monitoring Extension
24th Aug 20217:00 amRNS£8.1m Asthma Human Challenge Study Contract Win
9th Aug 20217:00 amRNSMalaria Human Challenge Model
29th Jul 20217:00 amRNSDNDi Phase II trial support
22nd Jul 20217:00 amRNSNEJM Opinion Piece
21st Jul 202112:58 pmRNSResult of AGM
14th Jul 20219:06 amRNSDirectors’ Dealings
14th Jul 20218:04 amRNSAIM Schedule 1 update by Poolbeg Pharma plc
14th Jul 20217:01 amRNSNew Contract win for Open Orphan’s Breda office
14th Jul 20217:00 amRNSCOVID-19 Human Challenge Programme update
9th Jul 20217:00 amRNSHRV and Flu contract
7th Jul 20214:41 pmRNSSecond Price Monitoring Extn
7th Jul 20214:36 pmRNSPrice Monitoring Extension
30th Jun 20217:00 amRNS2020 Annual Report and 2021 AGM Notice
17th Jun 20217:00 amRNSFinal Results to 31 December 2020
17th Jun 20217:00 amRNSDemerger Update
14th Jun 20217:00 amRNSRe. Distribution in Specie and Notice of Results
11th Jun 20217:00 amRNSExercise of Warrants
19th May 20217:00 amRNSCourt Approval
10th May 20217:15 amRNSExercise of Share Options
10th May 20217:00 amRNS£3m COVID challenge virus manufacturing contract
29th Apr 202111:39 amRNSResult of General Meeting
13th Apr 20217:00 amRNSPotential demerger of certain non-core assets
9th Apr 20217:00 amRNSLaunch of Disease in Motion platform
31st Mar 20217:00 amRNSHolding(s) in Company
26th Mar 20217:00 amRNS£7.5m Human Challenge Study Contract
25th Mar 20217:00 amRNSCOVID-19 Human Challenge Programme update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.